Tedizolid phosphate is a novel antibacterial prodrug. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. It also has effective activity a
Tedizolid HCl is a reversible, novel oxazolidinone antibiotic (IC50: for MAO-A (monoamine oxidase-A), 8.7 uM; for MAO-B, 5.7 uM). It is the first oxazolidinone to be approved since linezolid in 2000. Tedizolid phosphate is the second commercially availabl
DA-7867 is a novel oxazolidinone. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested (≤0.25 μg ml) and it was more potent than linezolid. DA-7867 was the most active drug with a MIC(90) of 0.125 μg ml.
Contezolid acefosamil sodium (MRX-4) is a novel orally active oxazolidinone antibiotic under investigation for the treatment of complicated skin and soft tissue infections (cSSTI) caused by drug-resistant Gram-positive bacteria. It possesses strong efficacy against these pathogens while significantly minimizing the risks of myelosuppression and monoamine oxidase inhibition (MAOI) [1][2].